肺癌免疫治疗进展教案.pptxVIP

肺癌免疫治疗进展 ;Future Outlook;Future Outlook;肿瘤免疫治疗—攻克肿瘤的新希望;;美国《Science》杂志: 2013年六大值得关注的科学领域 单细胞测序 “普朗克”探测微波背景辐射 人类连接组计划 探索南极冰下世界 癌症免疫疗法 基础植物研究;Breakthrough of year 2013;Immunity. 39(1)25 July 2013, Pages 1–10 ;CTLA-4 and PD-1/PD-L1 checkpoint blockade for cancer treatment;CTLA-4 and PD-1/PD-L1 Checkpoint Blockade for Cancer Treatment ;Comparing CTLA-4 and PD-1;Future Outlook; CTLA-4 Checkpoint Inhibitor;Anti-CTLA-4 antibodies can induce clinical response in a broad variety of cancer;;J Clin Oncol. 2012 Jun 10;30(17):2046-54;Kaplan–Meier plots for OS ;Events/patients 61/66 58/70 Median (95% CI), mo 4.21(2.76 to 5.32) 4.11 (2.76 to 5.32) HR (95% CI) 0.88 (0.61 to 1.27) Log-rank P .25;Adverse Events; Follow-UP Every 12 wks For survival;CA184-156: Phase III Trial Comparing the Efficacy of Ipi Plus Etoposide/Platinum Versus Etoposide/Platinum in Subjects With Newly Diagnosed ED-SCLC ;A Phase III Study of Nivolumab in Combination with Yervoy in Patients with Advanced Non-Small Cell Lung Cancer ; PD-1/PD-L1 Checkpoint Inhibitors;PD-1 and PD-L1 antibodies in phase III development ;Phase1 Nivolumab (anti-PD-1; BMS-936558, ONO-4538) multidose regimen;Select Aes(1%) occuring in Pts with NSCLC treated with Nivolumab(N=129);Efficacy of Nivolumab monotherapy in Pts treated with NSCLC ;Nivolumab in combination with PT-DC in advanced NSCLC;Results and Conclusions;Ongoing Nivolumab Clinical Trials in Patients With NSCLC;Parts C to F: Additional MEL and NSCLC cohorts;KEYNOTE-001：NSCLC扩大队列研究设计 (N=307);KEYNOTE-001：基线特征;KEYNOTE-001：治疗暴露与治疗相关不良事件汇总;KEYNOTE-001：肿瘤大小自基线最大变化*(%)(RECIST v1.1，中心评估);KEYNOTE-001：抗肿瘤活性(RECIST v1.1，中心评估);KEYNOTE-001：抗肿瘤活性 (irRC，研究者评估);KEYNOTE-001：至缓解时间 缓解持续时间;KEYNOTE-001：生存期评估：初治 vs. 复治;KEYNOTE-001：生存期评估：不同剂量;KEYNOTE-001：PD-L1表达水平与缓解率;KEYNOTE-001：生存期评估：PD-L1表达;KEYNOTE-001：总结与结论;;Ongoing MK-3475(Pem